Form 4: BioLife Solutions EVP Aby J. Mathew Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold common stock in multiple transactions under pre-arranged 10b5-1 trading plans.
Summary
- Aby J. Mathew, the EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported the sale of common stock in a series of transactions.
- The sales occurred on July 11, 2024, August 21, 2024, and September 16, 2024.
- These transactions were executed under Rule 10b5-1(c) trading plans adopted by Mathew on January 3, 2023, February 8, 2021, and February 24, 2022, respectively.
- The sales were intended to satisfy tax withholding obligations related to the vesting of restricted stock shares.
- On July 11, 2024, 313 shares were sold at a price of $20.54.
- On August 21, 2024, 111 shares were sold at a price of $25.61.
- On September 16, 2024, 343 shares were sold at a price of $25.12.
- Following these transactions, Mathew directly owns 317,716 shares of BioLife Solutions Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any positive or negative outlook.
Industry Context
Insider sales are a common occurrence, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information. The fact that these sales are related to tax obligations from vesting shares is also typical.
Key Dates
| Date | Description |
|---|---|
| 02/08/2021 | Date of adoption of a Rule 10b5-1(c) trading plan by the reporting person. |
| 02/24/2022 | Date of adoption of a Rule 10b5-1(c) trading plan by the reporting person. |
| 01/03/2023 | Date of adoption of a Rule 10b5-1(c) trading plan by the reporting person. |
| 07/11/2024 | Date of transaction: Sale of 313 shares of common stock at $20.54. |
| 08/21/2024 | Date of transaction: Sale of 111 shares of common stock at $25.61. |
| 09/16/2024 | Date of transaction: Sale of 343 shares of common stock at $25.12. |
| 09/18/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.